Financial statements from CiplaQCIL

May 21, 2019

End Year Results 2018 / 2019

CiplaQCIL

CiplaQCIL is a state-of-the-art pharmaceutical manufacturer based in Kampala, Uganda whose manufacturing facility was commissioned in 2009. In September 2018 CQCIL became the first publicly listed pharmaceutical company in East Africa following its successful Initial Public Offering on the Uganda Stock Exchange.

The Company focuses primarily on the production of high quality WHO pre-qualified first-line treatments for HIV/AIDS and Malaria. It also manufactures the two first-line WHO recommended therapies for Hepatitis B. CQCIL obtained regulatory approval for the new first line triple combination ARV therapy for males, tenofovir lamivudine dolutegravir, from NDA Uganda in January 2019. Additional regulatory approvals are anticipated in the next Quarter. CQCIL is one of the first companies to manufacture this new ARV on the African continent.

In the first half of this year, CiplaQCIL completed its Ushs 12 billion, 4,500 pallet storage facility, distribution centre and warehouse that will enable the consolidation of several existing facilities and will provide ample warehousing to support future growth. In addition, CQCIL completed a significant capacity enhancement project that has increased its monthly output capacity by 30% to approximately 130 million tablets per month.

In addition to its WHO pre-qualification, CQCIL has been approved by national regulatory bodies across Africa, including Uganda, Kenya, Rwanda, Tanzania, Namibia, Ivory Coast, Zambia, Zimbabwe, Malawi, Mozambique, Ghana, Ethiopia, Angola and South Sudan.

CLICK HERE FOR DETAILS

(adsbygoogle = window.adsbygoogle || []).push({});